BION-301 - First In Class anti-Pan KRAS biologics
KRAS, a pivotal oncogenic protein, plays a critical role in driving cancer progression and is commonly found to be mutated in diverse human malignancies.
Its abnormal activation due to these mutations results in unregulated cell proliferation, evasion of apoptosis, and increased survival of tumor cells. Recent research findings also indicate the potential involvement of wild type KRAS in the development of acquired resistance.
Biond is developing an anti Pan-KRAS biological inhibitor that can block the activity of WT as well as all the mutated KRAS forms. This agent will enable targeting a broad range of patients with different cancer indications.